Prenetics Group Limited (PRE): Price and Financial Metrics

Prenetics Group Limited (PRE): $1.81

-0.04 (-2.17%)

POWR Rating

Component Grades













PRE Stock Price Chart Interactive Chart >

Price chart for PRE

PRE Price/Volume Stats

Current price $1.81 52-week high $8.75
Prev. close $1.85 52-week low $1.24
Day low $1.77 Volume 40,900
Day high $1.85 Avg. volume 69,482
50-day MA $3.07 Dividend yield N/A
200-day MA $0.00 Market Cap 79.49M

Prenetics Group Limited (PRE) Company Bio

Prenetics Group Limited operates as a diagnostics and genetic testing company worldwide. It develops consumer genetic testing and early colorectal cancer screening products; and provides COVID-19 testing, rapid point of care and at-home diagnostic testing, and medical genetic testing products. The company's products include CircleDNA, a consumer genetic testing offering that uses whole exome sequencing; Project Screen, a COVID-19 test; and Circle HealthPod, a molecular testing product for COVID-19. It is also developing ColoClear, a non-invasive stool-based FIT-DNA test for colorectal cancer screening; Circle SnapShot, an at-home blood test with a user-friendly blood sample collection and result delivery system; Circle Medical, a test to identify causal genetic mutations for patients; and Circle One and F1x/Fem, a DNA profile and questionnaire based personalized nutrition solution. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

PRE Latest News Stream

Event/Time News Detail
Loading, please wait...

PRE Latest Social Stream

Loading social stream, please wait...

View Full PRE Social Stream

Latest PRE News From Around the Web

Below are the latest news stories about PRENETICS GLOBAL LTD that investors may wish to consider to help them evaluate PRE as an investment opportunity.

Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook

Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the second quarter ended June 30, 2022.

Yahoo | September 9, 2022

The past year for Prenetics Global (NASDAQ:PRE) investors has not been profitable

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

Yahoo | August 12, 2022

Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device

Prenetics Global Limited (NASDAQ: PRE), a global leader in genomic and diagnostic testing, announced the launch of Circle Snapshot, a variety of at-home blood tests that feature the world's first painless, patented, push-button blood collection device, to enable individuals to discover one's current health status from home.

Yahoo | August 8, 2022

What Kind Of Investors Own Most Of Prenetics Global Limited (NASDAQ:PRE)?

If you want to know who really controls Prenetics Global Limited ( NASDAQ:PRE ), then you'll have to look at the makeup...

Yahoo | July 16, 2022

Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test – ColoClear by Circle (ColoClear), for detecting early signs of colorectal cancer. Colorectal cancer is the second most common cancer in Hong Kong, accounting for 15.8% of total new cancers in 2019[1]. Combining advanced stool DNA technology with a faecal immunochemical test (FIT), the revolutionary test is the first line of defense against one of

Yahoo | June 8, 2022

Read More 'PRE' Stories Here

PRE Price Returns

1-mo -41.99%
3-mo -52.49%
6-mo -61.81%
1-year N/A
3-year N/A
5-year N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6679 seconds.